Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3427-3431

  Ge, Yigong ^a   Whitehouse, M J ^b   Friedland, Ian ^a   Talbot, George H ^c  

^a Calixa Therapeutics Inc   (United States)

^b JumpStart BioDevelopment   (United States)

^c Talbot Advisors LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CXA 101; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEADACHE; HUMAN; HYPESTHESIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VULVOVAGINAL DISEASE;

ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77955378731     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01753-09     Document Type: Article

References (17)

1. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, Jr., D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Brown, N. P., C. M. Pillar, D. C. Draghi, M. K. Torres, C. Thornsberry, D. F. Sahm, and Y. Ge. 2008. Activity profile of CXA-101 against gram-positive and gram-negative pathogens by broth and agar dilution, abstr. F1-354. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC, 25 to 28 October 2008.
3. Brown, N. P., C. M. Pillar, D. F. Sahm, and Y. Ge. 2009. Activity profile of CXA-101 and CXA-101/tazobactam against target gram-positive and gramnegative pathogens, abstr. F1-1986. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
4. European Medicines Agency. 2009. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. ECDC/EMEA joint technical report. http://www.emea.europa.eu/pdfs/human/antimicrobial-resistance /EMEA-576176-2009.pdf.
5. Falagas, M. E., and I. A. Bliziotis. 2007. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 29:630-636.
6. Ge, Y., and S. Liao. 2009. CXA-101 Population PK analysis and Monte Carlo simulation for PK/PD target attainment and dose regimen selection, abstr. F1-2003. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
7. Gin, A., L. Dilay, J. A. Karlowsky, A. Walkty, E. Rubinstein, and G. G. Zhanel. 2007. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev. Anti Infect. Ther. 5:365-383.
8. Giske, C. G., I. Karlsson, and Y. Ge. 2009. CXA-101 (CXA) has high activity against clinical isolates of Pseudomonas aeruginosa including ceftazidime-resistant isolates, abstr. F1-1988. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
9. Juan, C., L. Zamorano, J. L. Pérez, Y. Ge, and A. Oliver. 2010. Activity of a new cephalosporin CXA-101 (FR264205) against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54:846-851.
10. Livermore, D. M., and N. Woodford. 2006. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14: 413-420.
11. Moya, B., L. Zamorano, J. L. Pérez, Y. Ge, and A. Oliver. 2009. Affinity of the new cephalosporin CXA-101 (CXA) to penicillin-binding proteins (PBPs) of Pseudomonas aeruginosa, abstr. F1-1985. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
12. Moya, B., L. Zamorano, C. Juan, J. L. Pérez, Y. Ge, and A. Oliver. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against {beta}-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217.
13. Rice, L. B. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197:1079-1081.
14. Riera, E., M. D. Macia, A. Mena, X. Mulet, J. L. Pérez, Y. Ge, and A. Oliver. 2009. Activity of the new cephalosporin CXA-101 against biofilms of relevant P. aeruginosa (PA) phenotypes in cystic fibrosis chronic respiratory infection: mucoid and hypermutable strains, abstr. F1-1990. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
15. Spellberg, B., J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38:1279-1286.
16. Spellberg, B., R. Guidos, D. Gilbert, J. Bradley, H. W. Boucher, W. M. Scheld, J. G. Bartlett, and J. Edwards, Jr. 2008. The epidemic of antibiotic resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46:155-164.
17. Talbot, G. H. 2008. What is in the pipeline for gram-negative pathogens? Expert Rev. Anti Infect. Ther. 6:39-49.